PLX

Protalix BioTherapeutics Inc

Apr 09 • 03:43PM ET

2.29

+0.04 1.56 %

Healthcare • Biotechnology • USA • AMEX

Peers: SRPT BMRN ALNY FOLD ARWR BLUE QURE EDIT ABEO DTIL

Index	RUT	P/E	-	EPS (ttm)	-0.08	Insider Own	10.56%	Shs Outstand	80.43M	Perf Week	4.34%
Market Cap	184.11M	Forward P/E	32.64	EPS next Y	0.07	Insider Trans	0.66%	Shs Float	72.06M	Perf Month	-21.21%
Enterprise Value	161.45M	PEG	-	EPS next Q	-0.01	Inst Own	24.18%	Short Float	6.08%	Perf Quarter	28.37%
Income	-6.60M	P/S	3.49	EPS this Y	368.75%	Inst Trans	9.14%	Short Ratio	3.48	Perf Half Y	-8.60%
Sales	52.74M	P/B	3.81	EPS next Y	-67.44%	ROA	-8.48%	Short Interest	4.38M	Perf YTD	26.94%
Book/sh	0.60	P/C	5.94	EPS next 5Y	-	ROE	-14.44%	52W High	3.19 -28.37%	Perf Year	-2.35%
Cash/sh	0.38	P/FCF	-	EPS past 3/5Y	35.12% 17.78%	ROIC	-11.97%	52W Low	1.32 73.11%	Perf 3Y	3.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	3.45% -3.46%	Gross Margin	48.82%	Volatility	4.12% 4.82%	Perf 5Y	-56.56%
Dividend TTM	-	EV/Sales	3.06	EPS Y/Y TTM	-328.61%	Oper. Margin	-10.43%	ATR (14)	0.13	Perf 10Y	-74.61%
Dividend Ex-Date	-	Quick Ratio	1.54	Sales Y/Y TTM	-1.23%	Profit Margin	-12.52%	RSI (14)	45.58	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.51	EPS Q/Q	-179.91%	SMA20	-0.66%	Beta	0.01	Target Price	11.00
Payout	-	Debt/Eq	0.17	Sales Q/Q	-49.93%	SMA50	-12.62%	Rel Volume	0.58	Prev Close	2.25
Employees	226	LT Debt/Eq	0.14	Earnings	Mar 18 BMO	SMA200	12.25%	Avg Volume	1.26M	Price	2.29
IPO	Apr 09, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-250.00% -50.14%	Trades		Volume	698,037	Change	1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy	$3 → $11
Apr-17-17	Reiterated	Rodman & Renshaw	Buy	$4 → $5
Apr-04-16	Initiated	Rodman & Renshaw	Buy	$3.50
Apr-23-15	Upgrade	Jefferies	Hold → Buy	$2 → $2.60
Nov-12-14	Reiterated	R. F. Lafferty	Buy	$8 → $5
Jan-24-14	Initiated	R. F. Lafferty	Buy	$8
May-02-12	Reiterated	Oppenheimer	Outperform	$9 → $11
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold	$8 → $8
Apr-30-12	Downgrade	Auriga	Buy → Hold	$8 → $8
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy	$10
Nov-09-10	Reiterated	Oppenheimer	Outperform	$10 → $12
Oct-14-10	Reiterated	UBS	Buy	$9 → $10.75
Dec-02-09	Reiterated	Hapoalim	Outperform	$10 → $12
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform	$10
Dec-01-08	Reiterated	Oppenheimer	Outperform	$6 → $4
Mar-11-08	Initiated	UBS	Buy	$6
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform	$7

Show Previous Ratings

Mar-18-26 03:00PM	Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -20.79%
09:02AM	Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 (Proactive)
07:06AM	Protalix: Q4 Earnings Snapshot (Associated Press Finance)
06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results (PR Newswire)
Mar-11-26 06:50AM	Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 (PR Newswire)
03:43PM	Loading…
Mar-09-26 03:43PM	Nasdaq stays green as Middle East war sends oil above $103 (Proactive) +9.92%
10:40AM	Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen (Proactive)
Jan-05-26 06:50AM	Protalix BioTherapeutics Letter to Stockholders (PR Newswire)
Dec-17-25 06:50AM	Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement (PR Newswire)
Nov-13-25 02:05PM	Protalix BioTherapeutics Inc (PLX) Q3 2025 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com) -9.81%
06:55AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results (PR Newswire)
Nov-06-25 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 (PR Newswire) -6.72%
Sep-29-25 06:50PM	Protalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake Increase (Insider Monkey)
Sep-11-25 10:55AM	Protalix BioTherapeutics to Present at Investor Summit Virtual (ACCESSWIRE)
06:50AM	Loading…
Sep-02-25 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire) +5.81%
Aug-14-25 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results (PR Newswire) -5.59%
Aug-07-25 12:53PM	Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 (PR Newswire)
Jul-21-25 06:50AM	Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer (PR Newswire)
Jul-18-25 06:57AM	Fabry Disease Treatment Analysis Report 2025 \| Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth (GlobeNewswire)
Jun-30-25 06:50AM	Protalix BioTherapeutics Added to Russell 3000 and 2000 Indexes (PR Newswire)
May-14-25 06:50AM	Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC (PR Newswire)
May-10-25 03:04AM	Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
May-09-25 07:02AM	Protalix: Q1 Earnings Snapshot (Associated Press Finance) -40.48%
06:50AM	Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results (PR Newswire)
May-05-25 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 (PR Newswire) -5.33%
Apr-10-25 09:54AM	Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline (Seeking Alpha)
Mar-24-25 06:50AM	Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 (PR Newswire)
Mar-22-25 05:42PM	Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? (InsiderMonkey)
Mar-21-25 09:00AM	iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 (ACCESSWIRE) +5.51%
03:01AM	Loading…
Mar-18-25 03:01AM	Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Mar-17-25 06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results (PR Newswire) +9.38%
Mar-10-25 06:50AM	Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 (PR Newswire)
Feb-04-25 06:50AM	Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference (PR Newswire)
Dec-23-24 06:50AM	Protalix BioTherapeutics Issues 2025 Letter to Stockholders (PR Newswire)
Dec-10-24 10:35AM	EMA validates Chiesi and Protalixs dose variation for Fabry disease (Pharmaceutical Technology)
Dec-09-24 06:30AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa (PR Newswire)
Nov-15-24 02:10AM	Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
Nov-14-24 07:03AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance) +13.71%
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results (PR Newswire)
Nov-07-24 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 (PR Newswire)
Oct-25-24 07:18AM	Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 (PR Newswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
08:35AM	Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 (GlobeNewswire)
Sep-04-24 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) -5.61%
Sep-03-24 06:50AM	Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes (PR Newswire) +13.32%
Aug-30-24 08:38AM	Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-14-24 06:57AM	Protalix: Q2 Earnings Snapshot (Associated Press Finance) -10.58%
06:50AM	Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results (PR Newswire)
Aug-07-24 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 (PR Newswire)
Jun-13-24 06:50AM	Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout (PR Newswire)
May-29-24 08:38AM	Protalix BioTherapeutics to Present at the 2024 BIO International Convention (PR Newswire)
May-13-24 03:05AM	Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-11-24 10:27AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 06:56AM	Protalix: Q1 Earnings Snapshot (Associated Press Finance) -12.00%
06:50AM	Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results (PR Newswire)
May-03-24 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 (PR Newswire)
Mar-15-24 01:17PM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 08:11AM	Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023 (GuruFocus.com) -9.87%
06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results (PR Newswire)
Mar-07-24 06:50AM	Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 (PR Newswire)
Feb-23-24 06:50AM	Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference (PR Newswire)
Dec-26-23 06:50AM	Protalix BioTherapeutics Issues 2024 Letter to Stockholders (PR Newswire)
Nov-30-23 04:00AM	Levicept Appoints Eliot Forster as CEO (GlobeNewswire) +5.59%
Nov-07-23 09:04AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 08:04AM	Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results (GuruFocus.com) -18.38%
06:58AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results (PR Newswire)
Oct-30-23 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 (PR Newswire)
Oct-09-23 06:50AM	Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel (PR Newswire) -6.71%
Sep-12-23 06:50AM	Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors (PR Newswire)
Sep-06-23 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-08-23 09:14AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:51AM	PLX: Second Quarter Results (Zacks)
Aug-07-23 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results (PR Newswire) +14.46%
Aug-01-23 06:50AM	Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-31-23 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 (PR Newswire)
Jun-08-23 06:50AM	Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease (PR Newswire)
May-30-23 11:00AM	PLX: Back of the Envelope (Zacks Small Cap Research)
06:50AM	Protalix BioTherapeutics Issues Letter to Stockholders (PR Newswire)
May-23-23 06:50AM	Protalix BioTherapeutics set to join Russell 3000® Index (PR Newswire) +7.55%
May-18-23 06:50AM	Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases (PR Newswire) -9.32%
May-11-23 07:59AM	PLX: FDA Approval of Elfabrio (Zacks Small Cap Research) -13.27%
May-10-23 04:16PM	Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics (Benzinga)
06:00AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease (PR Newswire)
May-08-23 02:32AM	Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more (Investing.com) -7.03%
May-05-23 07:26AM	PLX: One Down, One to Go (Zacks Small Cap Research)
06:46AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease (PR Newswire)
May-04-23 06:50AM	Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results (PR Newswire) +6.67%
Apr-27-23 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023 (PR Newswire)
Mar-21-23 06:50AM	Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout (PR Newswire)
Mar-13-23 06:50AM	Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank (PR Newswire)
Feb-28-23 08:52PM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript (Insider Monkey)
04:32AM	PLX: May is a Big Month (Zacks Small Cap Research)
Feb-27-23 06:30AM	Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results (PR Newswire)
Feb-24-23 09:15AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease (PR Newswire) +7.06%
Feb-21-23 06:55AM	Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium 2023 (PR Newswire)
06:50AM	Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023 (PR Newswire)
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research) +6.99%

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bashan Dror	PRESIDENT AND CEO	Dec 19 '25	Buy	1.81	56,000	101,360	188,516	Dec 23 07:25 AM
Bar-Shalev Amos	Director	Nov 18 '25	Sale	1.87	168	314	0	Nov 19 04:34 PM
Schwartz Aharon	Director	Jun 10 '25	Buy	1.60	129,000	205,884	303,000	Aug 12 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLX

Protalix BioTherapeutics Inc

Upgrade your Finviz experience